title: New clinical trials with vitamin D and analogs in renal disease.
abstract: Two new clinical trials highlight refinements in the use of vitamin D and its analogs in the treatment of secondary hyperparathyroidism in end-stage renal disease (ESRD), and the treatment of proteinuria in diabetics. In patients with ESRD, alfacalcidol is as effective as paricalcitol in suppressing parathyroid hormone; the occurrence of hypercalcemia and hyperphosphatemia is infrequent and similar with the two analogs. Oral cholecalciferol reduces albuminuria and urinary transforming growth factor-β1 in patients with type 2 diabetes mellitus and proteinuria.
authors.forename: Rajiv
authors.initials: R
authors.lastname: Kumar
mesh_terms: D000419:Albuminuria / Q000188:drug therapy*; D002762:Cholecalciferol / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D003928:Diabetic Nephropathies / Q000188:drug therapy*; D004872:Ergocalciferols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006887:Hydroxycholecalciferols / Q000627:therapeutic use*; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy*; D008297:Male; D006435:Renal Dialysis / Q000009:adverse effects*; D012084:Renin-Angiotensin System / Q000187:drug effects*; D053773:Transforming Growth Factor beta1 / Q000652:urine*
chemical_list: D004872:Ergocalciferols; D006887:Hydroxycholecalciferols; D053773:Transforming Growth Factor beta1; D002762:Cholecalciferol; C084656:paricalcitol; C008088:alfacalcidol